Eplerenone vs. spironolactone in heart failure: a propensity score-matched analysis of 77 904 patients from a global federated network
J Cardiovasc Med (Hagerstown). 2026 Aug 1;27(8):659-669. doi: 10.2459/JCM.0000000000001929. Epub 2026 Jul 31.ABSTRACTBACKGROUND: Mineralocorticoid receptor antagonists (MRAs) reduce mortality in heart failure, yet whether eplerenone and spironolactone differ in effectiveness remains uncertain owing

